Abstract
With multiple clinical trials under way targeting mutant EGFR in patients with lung cancer, Maity and colleagues address important aspects of a MIG6-EGFR signaling axis using genetically engineered mouse models expressing mutated EGFRs on the MIG6-deficient background. This study extends our understanding of EGFR regulation by MIG6 and reveals that MIG6 antagonizes tumor formation in mutant EGFR-driven lung adenocarcinoma.
Original language | English (US) |
---|---|
Pages (from-to) | 472-474 |
Number of pages | 3 |
Journal | Cancer discovery |
Volume | 5 |
Issue number | 5 |
DOIs |
|
State | Published - May 1 2015 |
ASJC Scopus subject areas
- Oncology